Alto Neuroscience

Alto Neuroscience, founded in 2019, is a clinical-stage biopharmaceutical company dedicated to revolutionizing psychiatric treatment through precision medicine. By integrating deep neurobiological insights with artificial intelligence (AI), Alto aims to develop personalized and highly effective therapies for neuropsychiatric conditions such as major depressive disorder (MDD), bipolar depression, and schizophrenia.

The company has attracted significant investment from a diverse group of investors. In October 2021, Alto emerged from stealth with $40 million in funding to advance its clinical-stage pipeline of precision psychiatry medicines.

Alto’s uniqueness lies in its Precision Psychiatry Platform™, which utilizes AI to analyze brain biomarkers—including electroencephalogram (EEG) activity, behavioral patterns, wearable data, and genetics—to identify specific patient profiles. This approach enables the development of targeted treatments, addressing the challenge of variability in patient responses to psychiatric medications and aiming to improve therapeutic outcomes.

In the artificial intelligence landscape, Alto operates within the category of AI-driven precision psychiatry. Their technology applies machine learning algorithms to multimodal neurobiological data, facilitating the creation of personalized treatment strategies for mental health disorders.

For more information, please visit altoneuroscience.com.

To claim this startup page, go to the Contact page and send us a message with your full name, startup name, job title, and startup email address. We will review your request and get back to you. Once verified, you can update your startup information.